Executive Summary: Solving Lithotripsy Efficiency and Safety Limitations in Urologic Surgery
Urologists performing stone fragmentation and benign prostatic hyperplasia (BPH) surgery face a persistent trade-off: holmium:YAG (Ho:YAG) lasers, while effective, produce significant stone retropulsion, slower ablation rates, and require bulky, high-maintenance systems. Thulium fiber laser devices address these limitations by operating at 1940 nm—four times better absorbed by water than Ho:YAG—enabling faster fragmentation, minimal retropulsion, and dusting rather than fragmenting stones. As global urinary stone prevalence affects 720 million people and BPH affects 70-80% of aging men, demand for urologic laser lithotripsy solutions with improved efficiency and lower total cost of ownership is accelerating.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Fiber Dust Thulium Fiber Laser (TFL) Device – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Fiber Dust Thulium Fiber Laser (TFL) Device market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5514276/fiber-dust-thulium-fiber-laser–tfl–device
1. Market Sizing & Growth Trajectory
The global market for Fiber Dust Thulium Fiber Laser (TFL) Device was estimated to be worth US83.63millionin2025andisprojectedtoreachUS83.63millionin2025andisprojectedtoreachUS 213 million, growing at a CAGR of 14.5% from 2026 to 2032.
The thulium fiber laser (TFL) is a new technology as a conceivable alternative to the holmium: yttrium-aluminum-garnet (Ho: YAG) laser, which is currently the gold standard for an array of urologic procedures. Thulium fiber laser devices use long, thin, thulium-doped silica fiber as the active laser medium, offering superior beam quality and wall-plug efficiency.
Recent Market Data (Q1 2026): Global BPH laser surgery procedures using TFL reached 200,000 in 2025, while stone management procedures exceeded 580,000. According to survey data, global urinary stone prevalence is between 5-13% (average 9%), representing nearly 720 million people worldwide. Approximately 30 million people seek medical care for stones annually, with nearly 6 million requiring surgical intervention.
2. Technology Deep-Dive: TFL vs. Ho:YAG Comparison
Industry Segmentation Perspective – Why TFL is Displacing Legacy Holmium Lasers:
| Parameter | Thulium Fiber Laser (TFL) | Holmium:YAG (Ho:YAG) | TFL Advantage |
|---|---|---|---|
| Wavelength | 1940 nm (near water absorption peak) | 2100 nm | 4x water absorption |
| Stone retropulsion | Minimal (dusting mode) | Moderate-Severe | Faster procedure, less migration |
| Fiber diameter | 50-150 μm | 200-1000 μm | Better scope irrigation, tighter bends |
| Wall-plug efficiency | 15-25% | 1-5% | Lower power consumption, less cooling |
| Maintenance | Lower (solid-state fiber) | Higher (crystal rod degradation) | Reduced operating costs |
| Pulse frequency | Up to 2400 Hz | 10-100 Hz | Faster dusting, less thermal damage |
Technical Challenge – Adoption Barriers: Despite advantages, Ho:YAG alternative technology faces physician training inertia (urologists trained on holmium over 15+ years) and higher upfront capital cost (TFL: US120−180kvs.Ho:YAG:US120−180kvs.Ho:YAG:US 70-120k). However, lower disposables (fiber cost: TFL 200−400vs.Ho:YAG200−400vs.Ho:YAG400-800) and faster procedure times (30-40% reduction) improve total cost of ownership.
Exclusive Observation – The “Dusting Revolution”: TFL’s ability to operate at high frequency (500-2400 Hz) with low pulse energy enables “dusting”—fragmenting stones into fine dust particles that spontaneously pass, eliminating basket retrieval. This reduces procedure time by 35-50% and lowers ureteral injury risk from basket manipulation.
3. Procedure Volume & Geographic Adoption (2024-2025)
Global TFL Treatment Volumes (2024):
| Region | TFL Procedures (2024) | Market Share | Growth Outlook |
|---|---|---|---|
| Europe | 315,000 | 45% | Mature adoption, 12% CAGR |
| North America | 175,000 | 25% | Rapid acceleration (25% CAGR) |
| China | 50,000+ | 7% | Ultra-high growth (50% CAGR 2025-2030) |
| Rest of World | 160,000 | 23% | Emerging adoption |
Global TFL treatment operations reached 700,000 in 2024, with stone management exceeding 500,000 procedures. Global sales of thulium fiber laser devices exceeded 500 units in 2024, with top three manufacturers accounting for >40% market share.
Exclusive Insight – China as the Growth Engine: While holmium laser remains widely used in China, TFL urologic laser lithotripsy is showing rapid growth. By 2024, TFL surgeries in China exceeded 50,000, and we predict ultra-high annual growth of nearly 50% from 2025 to 2030, driven by (1) government central procurement of advanced technologies, (2) rapid expansion of private urology hospitals, and (3) strong domestic manufacturing (Raykeen, Potent, Rhein Laser).
4. Competitive Landscape & Market Share (2026 Estimate)
| Company | Headquarters | Core Strength | 2026 Est. Share | Key Differentiator |
|---|---|---|---|---|
| Quanta System | Italy | Lithotripsy specialization | 16% | Cyber Ho: high-frequency TFL |
| Olympus | Japan | Endoscope + laser integration | 14% | Complete OR workflow solution |
| OmniGuide (LISA Laser) | Germany | BPH enucleation focus | 11% | REVOLIX series (prostate optimized) |
| IPG Photonics | USA | Fiber laser technology leader | 9% | Highest power (up to 200W) |
| Electro Medical Systems (EMS) | Switzerland | Stone management | 7% | Swiss LithoClast combo |
| Raykeen | China | Domestic Chinese market | 6% | Price leader (30% below Western) |
| Others (Rocamed, Potent, Rhein, etc.) | Various | Regional & niche | 37% | Local service and support |
Market Dynamic (H1 2026): IPG Photonics launched a 200W TFL (industry highest) targeting large prostate enucleation, while Chinese manufacturer Raykeen gained 2.5 share points domestically following government tender wins.
5. User Case Analysis
Case 1 – High-Volume Lithotripsy Center (Germany): A tertiary referral center (1,200+ stone procedures annually) switched from Ho:YAG to Quanta System’s Cyber Ho TFL. Results (12 months): mean procedure time reduced from 52 to 34 minutes (35% improvement); stone-free rate increased from 82% to 91%; and fiber cost per case decreased from US480toUS480toUS 240.
Case 2 – BPH Enucleation (USA): A high-volume prostate surgeon performed 85 HoLEP (Holmium Laser Enucleation of Prostate) procedures annually. After transitioning to TFL (OmniGuide REVOLIX), enucleation time decreased from 48 to 31 minutes, and catheterization duration reduced from 24 to 16 hours. Patient satisfaction scores improved (less irritative symptoms).
Case 3 – Chinese Private Hospital (Shanghai): A 200-bed private urology hospital purchased four Raykeen TFL systems (US85,000eachvs.US85,000eachvs.US 150,000 for Western equivalents). Payback period: 8 months based on increased procedure volume (25% more cases per operating room day).
6. Segment Analysis (2026-2032 Forecast)
By Product Type:
| Segment | 2025 Share | CAGR | ASP | Primary Use |
|---|---|---|---|---|
| Low Power (<60W) | 35% | 12% | US$ 80-120k | Lithotripsy, small stones |
| High Power (≥60W) | 65% | 16% | US$ 120-200k | BPH enucleation, large stones |
By Application:
| Application | 2025 Share | CAGR | Key Driver |
|---|---|---|---|
| Stone Management | 65% | 14% | Dusting efficiency, reduced retropulsion |
| BPH Treatment | 28% | 16% | Faster enucleation, less bleeding |
| Others (Tumor, Stricture) | 7% | 12% | En bloc resection, endourethrotomy |
7. Selection Recommendations
- For high-volume lithotripsy (>300 cases/year): High-frequency TFL (Quanta, Olympus). Budget: US$ 120-150k.
- For BPH enucleation practice: High-power ≥100W with side-firing capability (OmniGuide, IPG). Budget: US$ 150-200k.
- For ambulatory surgery centers: Compact, low-maintenance TFL (EMS, Rocamed). Budget: US$ 90-120k.
- For emerging markets (China, India): Domestic TFL (Raykeen, Potent). Budget: US$ 70-90k.
8. Forecast & Strategic Recommendations (2026-2032)
Three inflection points will reshape the thulium fiber laser device market:
- TFL as New Gold Standard (2026-2029): Major urology societies (EAU, AUA) expected to elevate TFL to preferred status for stones <2cm by 2028.
- Fiber Optic Innovations (2027-2029): Single-use ultra-thin fibers (50μm) enabling use in flexible ureteroscopes without tip deflection loss.
- AI-Assisted Laser Settings (2028+): Automated parameter selection based on stone composition (real-time analysis).
Strategic Recommendations: For Western OEMs, focus on BPH (higher ASP, less price-sensitive). For Asian entrants, target domestic stone management with aggressive pricing. All players must invest in urologist training programs to accelerate adoption.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
